The tender offer for Nissui Pharmaceutical: into diagnostics (2022)

How far away “adjacent” really is

To read this acquisition as an instrument maker jumping into the pharmaceutical business is to mistake its character. What Shimadzu went after was not medicines but the things its own mass spectrometers and PCR systems measure — the clinical specimen, and the reagents and culture media used on it. The aim was to convert a relationship that ended when the instrument was sold into one that reaches into the testing floor itself, reagents and media included. Seven years passed between the 2015 business alliance and the purchase of equity, time spent taking the measure of the partner. It can be read as extending the outlet for measurement technology into diagnosis.

That said, a field that looks adjacent does not translate straight into profit. In-vitro diagnostics and clinical testing are heavily regulated and fiercely priced, and existing reagent makers have deep roots there. The offer price of $13 (¥1,714) per share, more than 70% above the previous close, was itself a number that valued the target’s future generously in advance. How much of the technology built up in analytical measurement turns into earnings on the clinical floor depends on how far Shimadzu Diagnostics can grow the testing business from here.